Hints and tips:
....; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC...
...Worse for Teva, it doubled down on generics by paying roughly $40bn for Allergan’s Actavis unit — just before prices started to crumble and after some investors warned against the deal....
...The Indian groups, which enjoy much lower labour costs, had been flooding the global market with cheaper pills, but they failed to meet stringent manufacturing standards for US imports....
...Both pharmacy benefits managers and pharmacy retailers have been active in striking deals in recent years, in an effort to exert pressure on generic and specialty pharma drugmakers....
...HSBC’s preliminary purchasing managers index for China’s manufacturing sector hit 48.3, signalling that activity contracted for a fourth month in April....
...The market is delighted by Watson Pharmaceuticals’ €4.5bn acquisition of Switzerland’s Actavis....
...The pharma sector yielded two relatively large deals....
...Astra, the world’s fifth largest pharma company by sales, is not out of the woods entirely....
...of low-cost manufacturing....
...At the time it was competing against Teva of Israel, Actavis of Iceland, Stada from Germany and then a private equity consortium consisting of Apax and Bain Capital....
International Edition